Score Against Cancer are delighted to announce a new partnership with Cancer Research UK.
Over the past 2 years, we’ve supported the Bobby Moore Fund and Cancer Research UK with various charitable events and live streams and we’re ecstatic to be able to announce a three-year partnership with the charity.
During the course of this partnership, we’ll be more actively involved in promoting Bobby Moore Fund and Cancer Research initiatives, putting on more events and aiming for much larger targets than ever before.
We are delighted to be partnering with Score Against Cancer in the battle to beat bowel cancer. Bowel cancer is much more common as we get older, with 9 out of 10 cases diagnosed in people over 50, but it’s never too early to think about reducing your risk. The passing of TotalBiscuit is a stark reminder of the impact of this disease. Through this partnership we aim to engage a wider audience with our work. Together we will beat bowel cancer
Using our collective audiences, the aim is to raise awareness and funding to help prevent and cure bowel cancer, which is an incredibly preventable disease and highly treatable if caught early. Score Against Cancer believes that over the course of this partnership, we can utilise our resources effectively to help make this a success.
Score Against Cancer’s founder, Ash Francis had this to say:
I’m absolutely delighted to be able to announce this partnership ahead of our third year. We’ve already put so much in place and over the next three years, this partnership will help us to do so much more towards reaching our collective goals as well as furthering the individual brands of Score Against Cancer and The Bobby Moore Fund. Bowel Cancer has long been seen as an old man’s disease, but that’s absolutely not the case, and by working closely with Cancer Research Uk and the Bobby Moore Fund, we can get people taking the right steps earlier in life and preventing this disease.
The partnership is scheduled to run until 2021 and will involve collaborative efforts from Score Against Cancer and Cancer Research UK.